Anzeige
Mehr »
Mittwoch, 13.08.2025 - Börsentäglich über 12.000 News
Diese Aktie liegt in der Turbo-Zone - und könnte der Gold-Gewinner 2025/26 werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CRAU | ISIN: SE0015988373 | Ticker-Symbol: 7D2A
Tradegate
12.08.25 | 15:42
1,520 Euro
+2,15 % +0,032
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SEDANA MEDICAL AB Chart 1 Jahr
5-Tage-Chart
SEDANA MEDICAL AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,5101,54412.08.
1,5221,54412.08.

Aktuelle News zur SEDANA MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.07.Sedana Medical AB: Sedana Medical AB's Interim report January-June 2025129Promising US data and strong sales growth in Q2 Second quarter 2025Net sales for the quarter totalled MSEK 49.8 (41.1), equivalent to an increase of 21% compared to the corresponding quarter 2024. At...
► Artikel lesen
06.05.Sedana Medical AB: Sedana Medical AB's Interim report January-March 2025132Early Access in the US and a record quarter First quarter 2025Net sales for the quarter totalled MSEK 57.5 (48.8), equivalent to an increase of 18% compared to the corresponding quarter 2024. At constant...
► Artikel lesen
23.04.Sedana Medical AB: Sedana Medical Receives FDA Approval for Early Access Program in the U.S.151Sedana Medical AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's application to initiate an Early Access Program for its investigational inhaled sedation...
► Artikel lesen
SEDANA MEDICAL Aktie jetzt für 0€ handeln
13.02.Sedana Medical AB: Sedana Medical AB's Year-end report 2024202Primary endpoint met in both US trials and positive ex-US EBITDA excl. one-offs in Q4 Fourth quarter 2024Net sales for the quarter totalled MSEK 49.2 (44.5), equivalent to an increase of 10% compared...
► Artikel lesen
12.02.Sedana Medical AB: Sedana Medical announces positive high-level results also for its second pivotal trial in the United States219Sedana Medical AB (publ) announces that its second pivotal US trial INSPiRE-ICU 2 has met its primary endpoint, and hence established non-inferiority of inhaled sedation with isoflurane compared with...
► Artikel lesen
03.02.Sedana Medical AB: Sedana Medical receives an additional year of market protection for Sedaconda (isoflurane)327Sedana Medical AB (publ) announces that Sedaconda® (isoflurane) has received an additional year of market protection, extending the protection period until 2032. The decision is based on the regulatory...
► Artikel lesen
19.12.24Sedana Medical AB: Sedana Medical announces positive high-level results of its first pivotal trial in the United States (INSPiRE-ICU 1)283Sedana Medical AB (publ) announces that its first pivotal US trial INSPiRE-ICU 1 has met its primary endpoint: to prove that inhaled sedation with isoflurane is an effective sedation method by establishing...
► Artikel lesen
24.10.24Sedana Medical AB: Sedana Medical AB's Interim report January-September 2024193Raising our 2024 sales guidance and integrating our European trial into the US submission - strengthening our file, but extending timelines Third quarter 2024Net sales for the quarter totaled MSEK 39.7...
► Artikel lesen
8 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1